Peptide inhibitors as novel anti-HIV therapeutics

Patent metadata

Field	Value
Publication number	US-9327009-B2
Application number	US-201314382428-A
Country	US
Kind code	B2
Filing date	Mar 1, 2013
Priority date	Mar 2, 2012
Publication date	May 3, 2016
Grant date	May 3, 2016

Abstract

The present invention relates to synthetic peptide inhibitors (Seq ID No. 67-71) useful as anti-HIV therapeutics. The invention also relates to a novel screening method for screening anti-HIV molecules. The present invention relates to a synthetic peptide useful as anti-HIV therapeutic. The invention also relates to a novel screening method for screening of anti-HIV therapeutics. In particular, the present invention relates to reporter gene constructs for the detection of the HIV Nef and host ASK1 protein interaction. Furthermore, the invention relates to a functional interaction for Nef-ASK1 proteins prepared in a recombinant manner, a method for identifying of Nef-ASK1 interaction which causes activation of pathway to activate apoptosis presumably causing immune evasion for HIV in infected cells. The reporter gene construct according to the present invention, after it had been introduced into cells, in the presence of HIV Nef and host ASK1 proteins result in the expression of reporter luciferase protein which may be used for quantitative/qualitative interaction of HIV Nef and host ASK1 protein. The both interacting construct cloned in fluorescence expression vector when transfected in eukaryotic cells inhibits ASK1 mediated apoptosis and were reversed by the inhibitors. Furthermore, the invention was used to identify the inhibitor for the interaction of Nef-ASK1 in the cell.

First claim

The invention claimed is:

1. A synthetic peptide useful as anti-Human Immunodeficiency Virus (anti-HIV) therapeutic having the sequence of SEQ ID NO. 69.

2. A method for screening anti-HIV molecules comprising the steps of:
a. transfecting constructs of SEQ ID No. 1, 3 and 16 into a mammalian cell using 5 μl of a transfection reagent to obtain a transfected cell;
b. analyzing the transfected cell as obtained in step (a) for luciferase activity after incubating for a period of 48 hours for demonstrating Negative factor (Nef)-Apoptosis signal regulating kinase 1 (ASK1) interaction;
c. adding the molecule to be screened in the transfected cell of step [a] and incubating for 6 to 24 hours followed by repeating step [b] to assess its inhibitory activity on the Nef-ASK1 interaction;
d. selecting the molecules which are inhibiting the Nef-ASK1 interaction resulting in no additional luciferase activity with respect to the control as a potential anti-HIV therapeutic.

3. The method as claimed in claim 2 wherein the construct of SEQ ID NO. 1 represents Nefwt gene cloned in VP16pCDNA+pACT vector.

4. The method as claimed in claim 2 wherein the construct of SEQ ID NO. 16 represents ASK1 gene cloned in pBIND vector.

5. The method as claimed in claim 2 wherein the construct of SEQ ID NO. 3 represents the reporter constructs pG5Luc.

6. The method as claimed in claim 2 wherein the mammalian cell is selected from the group consisting of T cell lines, monocytic cell lines and fibroblast cells wherein Nef-ASK1 interaction is established.

7. The method as claimed in claim 2 wherein the molecule to be screened is added at a concentration of 5 to 1.25 μm.

8. The method as claimed in claim 2 wherein the molecule screened as a potential anti-HIV therapeutic is a synthetic peptide having a sequence of SEQ ID NO. 69 (DEVGEANN).

9. A pharmaceutical composition comprising a therapeutically effective amount of a synthetic peptide selected from the group consisting of: a synthetic peptide having the sequence of SEQ ID NO. 69 , a functional variant of the synthetic peptide having the sequence of SEQ ID NO. 69 , functional derivative of the synthetic peptide having the sequence of SEQ ID NO. 69 , a pharmaceutically acceptable salt of any of the foregoing, along with a pharmaceutically acceptable excipient, wherein said peptide or pharmaceutically acceptable salt thereof inhibits the fusion of HIV Nef to human ASK 1.

10. A method of treating HIV infection that comprises providing to a recipient a therapeutically effective or a prophylactically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of a peptide selected from the group consisting of: a synthetic peptide having the sequence of SEQ ID NO. 69, a functional variant of the synthetic peptide having the sequence of SEQ ID NO. 69, a functional derivative of the synthetic peptide having the sequence of SEQ ID NO. 69 and a functional pharmaceutically acceptable salt of any of the foregoing, wherein said peptide or pharmaceutically acceptable salt thereof inhibits the fusion of HIV-Nef to human ASK1 along with a pharmaceutically acceptable excipient.

11. The method as claimed in claim 2 , wherein the molecule to be screened comprises the synthetic peptide of claim 1 .

12. A method of inhibiting the binding effect of HIV-Nef to human ASK1 by reversing the c-Jun N-terminal kinases (JNK) phosphorylation, the method comprising providing to a recipient a therapeutically effective amount of a synthetic peptide having SEQ. ID NO. 69.

Assignees

• Council Scient Ind Res
• Council Scient Ind Res

Inventors

• Tripathi Raj Kamal
• Kumar Balawant
• Ramachandran Ravishankar
• Tripathi Jitendra Kumar
• Bhadauria Smriti
• Ghosh Jimut Kanti

Classifications

• C07K14/005

  from viruses · CPC title

• G01N33/5041

  involving analysis of members of signalling pathways · CPC title

• C07K2/00

  Peptides of undefined number of amino acids; Derivatives thereof · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61P31/18

  for HIV · CPC title